Effects of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Cancer Induced Bone Pain Relief in Patients with Non-Small Cell Lung Cancer: Study Protocol for a Randomized Controlled Trial

• Published in: Journal of pain research 2024-01, Vol.17, p.1285-1298
• Main Authors: Lyu, Zhengyi, Shen, Qiongying, Tian, Shuxin, Gong, Liyan, Lou, Haizhou, Bao, Guanai, Wu, Zhuoxuan, Lu, Chao, Zhang, Weiping, Huang, Rui, Ji, Conghua, Zheng, Siyi, Pan, Wei, Ying, Yinyin, Jin, Jianwei, Liang, Yi
• Format: Article
• Language: English
• Subjects: Acupuncture; Adjuvant treatment; bone cancer pain; Cancer; Care and treatment; Clinical trials; Evidence-based medicine; home-based treatment; integrative medicine; Lung cancer, Non-small cell; Lung cancer, Small cell; Medical centers; Metastasis; Oncology, Experimental; Opioids; Pain; patient-controlled analgesia; teas; transcutaneous electrical nerve stimulation
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S437296

Transcutaneous Electrical Acupoint Stimulation (TEAS) therapy opens up the possibility for individuals with Cancer-induced bone pain (CIBP) to receive a home-based, patient-controlled approach to pain management. The aim of this study is designed to evaluate the efficacy of patient-controlled TEAS (PC-TEAS) for relieving CIBP in patients with non-small cell lung cancer (NSCLC). This is a study protocol for a prospective, triple-blind, randomized controlled trial. We anticipate enrolling 188 participants with NSCLC bone metastases who are also using potent opioid analgesics from 4 Chinese medical centers. These participants will be randomly assigned in a 1:1 ratio to either the true PC-TEAS or the sham PC-TEAS group. All participants will receive standard adjuvant oncology therapy. The true group will undergo patient-controlled TEAS intervention as needed, while the sham group will follow the same treatment schedule but with non-conductive gel patches. Each treatment course will span 7 days, with a total of 4 courses administered. There will be 4 assessment time points: baseline, the conclusion of weeks 4, 8, and 12. The primary outcome of this investigation is the response rate of the average pain on the Brief Pain Inventory (BPI) scale at week 4 after treatment. Secondary outcomes include pain related indicators, quality of life scale, mood scales, and routine blood counts on the assessment days. Any adverse events will be promptly addressed and reported if they occur. We will manage trial data using the EDC platform, with a data monitoring committee providing regular quality oversight. PC-TEAS interventions offer an attempt to achieve home-based acupuncture treatment and the feasibility of achieving triple blinding in acupuncture research. This study is designed to provide more rigorous trial evidence for the adjuvant treatment of cancer-related pain by acupuncture and to explore a safe and effective integrative medicine scheme for CIBP. ClinicalTrials.gov NCT05730972, registered February 16, 2023.